Cell Reports (Oct 2013)

A BRISC-SHMT Complex Deubiquitinates IFNAR1 and Regulates Interferon Responses

  • Hui Zheng,
  • Vibhor Gupta,
  • Jeffrey Patterson-Fortin,
  • Sabyasachi Bhattacharya,
  • Kanstantsin Katlinski,
  • Junmin Wu,
  • Bentley Varghese,
  • Christopher J. Carbone,
  • Bernadette Aressy,
  • Serge Y. Fuchs,
  • Roger A. Greenberg

DOI
https://doi.org/10.1016/j.celrep.2013.08.025
Journal volume & issue
Vol. 5, no. 1
pp. 180 – 193

Abstract

Read online

Lysine63-linked ubiquitin (K63-Ub) chains represent a particular ubiquitin topology that mediates proteasome-independent signaling events. The deubiquitinating enzyme (DUB) BRCC36 segregates into distinct nuclear and cytoplasmic complexes that are specific for K63-Ub hydrolysis. RAP80 targets the five-member nuclear BRCC36 complex to K63-Ub chains at DNA double-strand breaks. The alternative four-member BRCC36 containing complex (BRISC) lacks a known targeting moiety. Here, we identify serine hydroxymethyltransferase (SHMT) as a previously unappreciated component that fulfills this function. SHMT directs BRISC activity at K63-Ub chains conjugated to the type 1 interferon (IFN) receptor chain 1 (IFNAR1). BRISC-SHMT2 complexes localize to and deubiquitinate actively engaged IFNAR1, thus limiting its K63-Ub-mediated internalization and lysosomal degradation. BRISC-deficient cells and mice exhibit attenuated responses to IFN and are protected from IFN-associated immunopathology. These studies reveal a mechanism of DUB regulation and suggest a therapeutic use of BRISC inhibitors for treating pathophysiological processes driven by elevated IFN responses.